When it comes to advancements in treating blood cancers, 2017 was a particularly exciting year, with well over a dozen new therapies or indications approved by the Food and Drug Administration (FDA). The Leukemia & Lymphoma Society has played a role in at least 10 of these new drugs or medication uses at some point throughout their development and approval process.
To take the next step in this research, investigators are now combining immunotherapies together, or with chemotherapy, to create added benefits and more durable, long-lasting responses.
Hospital readmissions soon after discharge can be costly and detrimental to patient care, but according to a recent study conducted at the Cleveland Clinic and presented at the 2017 American Society of Hematology’s Annual Meeting and Exposition, creating an interdisciplinary team to work with patients can help.
There were monumental advances in the treatment of bladder cancer during the year 2017, with five approvals for checkpoint inhibitors in both the first and second line setting
When given neoadjuvant chemotherapy before getting a radical cystectomy, patients with the basal subtype of muscle-invasive bladder cancer (MIBC) saw significantly improved overall survival (OS) compared to those who had a cystectomy alone, according to a recent study.
When it comes to cancer research, the Internet can be used for good or bad.
An individualized treatment summary and care plan reduced treatment-related distress among patients who previously underwent hematopoietic cell transplantation (HCT) for cancer treatment.
I certainly am not like some people who try to present the perfect façade of their lives, but I do not want to be a downer, either.
Patients aged 75 years or older diagnosed with hematologic malignancies appear significantly underrepresented in clinical trials submitted to the U.S. Food and Drug Administration (FDA), according to a retrospective analysis.
From diagnosis to remission, my sister had cancer for nearly three years. Because of that, the cancer dates that mark my calendar are plentiful. I can recall most of them from memory without a second glance. While I was recently going through my old planners, I noticed just how many dates are filled with notations of cancer.
Keytruda (pembrolizumab) was granted a priority review to a supplemental biologics license application (sBLA) to be used to treat adult and pediatric patients with relapsed or refractory primary mediastinal large B-cell lymphoma (PMBCL).
Previous studies have found that caregivers of HCT recipients have more sleep and sexual issues, more depressive symptoms and more loneliness, as well as less social support and less spiritual well-being than HCT recipients.
“It was frustrating always being the youngest one in the waiting room, combined with the fact that there is just not a lot of data on this population. So, we are forced to make decisions in the absence of hard data. It’s frustrating to know that we’re the neglected cohort of the disease,” Petrides said.
The famous philosopher Nietzsche once said, “He who has a why to live can bear almost any how.”
Treatment decisions are not always easy, but this is one I don't regret making.
Chronic pain is a serious side effect of many cancer treatments. Medical marijuana is currently being suggested as an alternative option to traditional opioid medications.
Even people with health insurance may face financial toxicity as they try to stay on top of medical bills and other disease-related costs.
At this year's Annual ASH Meeting & Exposition, eight people were recognized as MPN Heroes, and, new this year, a ninth individual was honored as the program’s first Canadian MPN Champion - all for their commitment to the individual and commitment to the broader MPN community.
The Mattie Miracle Cancer Foundation is dedicated to addressing the psychological needs of children and families with childhood cancer. It also aims to educate health care providers about potential psychosocial effects of a diagnosis.
Two-time cancer survivor offers ways to reduce clutter during the holidays and beyond.
A supplemental new drug application (sNDA) for Rubraca (rucaparib), a PARP inhibitor, has been granted a priority review by the Food and Drug Administration.
Key takeaways from the National Comprehensive Cancer Network® (NCCN)’s Patient Advocacy Summit reveal progress made toward improving survivorship care and planning, and identify opportunities for improvement.
The FDA has granted Avastin (bevacizumab) a full approval for the treatment of adult patients with glioblastoma who progressed following prior therapy, according to Genentech, the manufacturer of the VEGF inhibitor.
Patient Advocacy Summit brings together advocacy organizations and other key stakeholders to share ideas about how to improve survivors’ quality of life.
A study finds that patients often turn to the internet for information regarding their cancer diagnosis, but more often than not, they still rely on healthcare providers in their decision-making process.
Longer time in between pre- and postoperative chemotherapy may be associated with significantly worse survival outcomes in women with ovarian cancer.
The notion then, that disease outcome (whether you live or die) determines if you are a survivor is therefore erroneous.
At the National Comprehensive Cancer Network® (NCCN)’s Patient Advocacy Summit – a meeting designed to share best practices for survivorship planning care among advocacy organizations – Yelak Biru shared his story of survivorship, and how he has been able to integrate multiple myeloma into his life for more than two decades.
Learning to accept the physical changes breast cancer creates is often difficult, but doable. It takes time to learn to embrace change but doing so is beneficial to well being.
During cancer treatment, patients lose a lot of things, but one thing that’s constantly noticed is hair loss.
